SciClone Pharmaceuticals (Holdings) (HKSE:06600) Cash And Cash Equivalents : HK$1,979 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is SciClone Pharmaceuticals (Holdings) Cash And Cash Equivalents?

SciClone Pharmaceuticals (Holdings)'s quarterly cash and cash equivalents declined from Dec. 2022 (HK$1,866.96 Mil) to Jun. 2023 (HK$1,763.21 Mil) but then increased from Jun. 2023 (HK$1,763.21 Mil) to Dec. 2023 (HK$1,978.86 Mil).

SciClone Pharmaceuticals (Holdings)'s annual cash and cash equivalents declined from Dec. 2021 (HK$2,605.04 Mil) to Dec. 2022 (HK$1,866.96 Mil) but then increased from Dec. 2022 (HK$1,866.96 Mil) to Dec. 2023 (HK$1,978.86 Mil).

SciClone Pharmaceuticals (Holdings) Cash And Cash Equivalents Historical Data

The historical data trend for SciClone Pharmaceuticals (Holdings)'s Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SciClone Pharmaceuticals (Holdings) Cash And Cash Equivalents Chart

SciClone Pharmaceuticals (Holdings) Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

1,023.16

1,326.48

2,605.04

1,866.96

1,978.86

SciClone Pharmaceuticals (Holdings) Semi-Annual Data
	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial						2,605.04	1,538.77	1,866.96	1,763.21	1,978.86

SciClone Pharmaceuticals (Holdings) Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

SciClone Pharmaceuticals (Holdings) Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of SciClone Pharmaceuticals (Holdings)'s Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SciClone Pharmaceuticals (Holdings) Ltd (HKSE:06600) » Definitions » Cash And Cash Equivalents

Traded in Other Exchanges

N/A

Address

381 Middle Huaihai Road, 22nd Floor, Central Plaza, Shanghai, CHN

Website

https://www.sciclone.com

SciClone Pharmaceuticals (Holdings) Ltd is a biopharmaceutical company with an integrated platform for product development and commercialization. It strategically focuses on some of the fast-growing therapeutic areas with unmet medical needs in China, primarily including oncology and severe infection. It generated revenue primarily from the sale of Zadaxin to Sinopharm.

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Headlines

No Headlines